Sign In
Buy JAZZ
$230.93
+4.81 (+2.13%)
At Close: Jun 03, 2026
Ardent value investor Seth Klarman is swapping out shares of search engine juggernaut Alphabet for a relatively unknown pharmaceutical stock that has a forward price-to-earnings ratio of 5!
Wall Street Analysts Think Jazz (JAZZ) Could Surge 51.8%: Read This Before Placing a Bet
10:55am, Thursday, 17'th Oct 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 51.8% in Jazz (JAZZ). While the effectiveness of this highly sought-after metric is questionable, the positive
Are Investors Undervaluing Jazz Pharmaceuticals (JAZZ) Right Now?
10:45am, Thursday, 17'th Oct 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
12:45pm, Wednesday, 16'th Oct 2024
Investors interested in Medical - Drugs stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity
JAZZ Stock Soars After Combo Therapy Meets Goal in Lung Cancer Study
10:55am, Wednesday, 16'th Oct 2024
Data from a late-stage study showed that Jazz's Zepzelca, combined with Roche's Tecentriq, improved survival rates in certain patients with small-cell lung cancer.
Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook
08:39am, Wednesday, 16'th Oct 2024
Shares of Jazz Pharmaceuticals are trading only slightly higher in the last few weeks despite two unexpected wins. The partial legal win against Avadel helps protect Jazz's market position in idiopath
Jazz Pharmaceuticals plc JAZZ revealed topline results from the Phase 3 clinical trial evaluating Zepzelca (lurbinectedin) in combination with the PD-L1 inhibitor Roche Holdings AG's RHHBY atezolizum
Jazz plans to submit supplemental New Drug Application in first half of 2025 for this combination therapy as a first-line maintenance treatment for ES-SCLC DUBLIN , Oct. 15, 2024 /PRNewswire/ -- Jazz
Jazz Pharmaceuticals: Unveiling Growth Potential From Non-Small Cell Lung Cancer Market
09:00am, Friday, 04'th Oct 2024
Jazz Pharmaceuticals (JAZZ, Financial), a leading player in the narcolepsy market, is expanding its reach into other markets such as the non-small cell lung cancer (NSCLC) market by preparing a new bi
Here's Why You Should Consider Buying Jazz Pharmaceuticals' Stock
12:16pm, Wednesday, 02'nd Oct 2024
Here, we discuss some reasons why buying JAZZ stock now may turn out to be a prudent move.
Is Jazz Pharmaceuticals (JAZZ) Stock Undervalued Right Now?
10:45am, Tuesday, 01'st Oct 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Phase 2 updated results for zanidatamab in HER2-positive mGEA included a confirmed objective response rate (cORR) of 84%, duration of response (DoR) of 18.7 months, median progression-free survival (m
Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024
07:58am, Monday, 09'th Sep 2024
New and updated data from an ongoing Phase 2 trial of zanidatamab, an investigational dual HER2-targeted bispecific antibody, in combination with chemotherapy for first-line treatment of HER2-positive
Data from eight abstracts to be presented, including results of the BECOME (BEhavior, COgnition and More with Epidyolex®) Caregiver Survey on the real-world outcomes of Epidyolex® (cannabidiol) trea
DUBLIN , Sept. 4, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced the pricing of $850 million aggregate principal amount of 3.125% exchangeable s
